← Back to Search

CXL with MMC for Keratoconus

Phase 2
Waitlist Available
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 3 months, 6 months, 12 months and 18 months post-operation.
Awards & highlights

Summary

This trial tests whether applying a small amount of mitomycin C to the eye can reduce cloudiness and scarring in patients with early-stage corneal disorders who have had corneal crosslinking. The goal is to improve their vision quality by reducing inflammation and scarring. Mitomycin C has been widely used in various eye procedures to minimize scarring and improve outcomes, demonstrating effectiveness in reducing haze and scarring in several studies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 3 months, 6 months, 12 months and 18 months post-operation.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 3 months, 6 months, 12 months and 18 months post-operation. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Corneal haze/scarring
Secondary study objectives
Clinical haze grade
Glare
Higher-order aberrations

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CXL with MMCActive Control1 Intervention
Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
Group II: CXL without MMCPlacebo Group1 Intervention
Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).

Find a Location

Who is running the clinical trial?

Ciusss de L'Est de l'Île de MontréalLead Sponsor
77 Previous Clinical Trials
6,333 Total Patients Enrolled
~1 spots leftby Sep 2025